Skip to main content

Table 2 Survival analysis of the clinical pathological parameters

From: Clinicopathological and prognostic significance of GPX2 protein expression in esophageal squamous cell carcinoma

Clinical features Cases Mortality MST (95 % CI) Log-rank P value HR (95 % CI)
Age
 ≤ 58 years 45 35 26 (16.141~38.859) 0.850 1.049 (0.637~1.725)
 > 58 years 38 28 18 (5.918~30.082)   
Sex
 Male 60 46 26 (13.348~38.652) 0.796 1.075 (0.616~1.876)
 Female 23 17 18 (8.609~27.391)   
Size
 ≤ 4.5 cm 48 35 29 (17.118~40.882) 0.339 1.270 (0.772~2.088)
 > 4.5 cm 35 28 19 (4.512~33.488)   
Site
 Upper 9 6 33 (0~73.905) 0.028 1.803 (0.992~3.278)
 Middle 65 48 29 (18.467~39.533)   
 Below 9 9 11 (5.156~16.844)   
Gross morphology
 Medullary 62 46 30 (9.755~50.245) <0.001 1.252 (0.942~1.663)
 Umbrella 5 4 9 (6.853~11.147)   
 Ulcer 13 10 20 (10.605~29.395)   
 Stenosis 3 3 6 (4.400~7.600)   
Histological grade
 I 32 20 47 (10.966~83.034) 0.009 1.885 (1.212~2.932)
 II 46 38 20 (8.616~31.384)   
 III 5 5 8 (5.853~10.147)   
TNM stages
 I~II 49 32 42 (22.796~61.204) 0.007 2.046 (1.318~3.177)
 III 32 29 14 (6.608~21.392)   
 IV 2 2 -   
Treatment
 No 41 31 19 (3.944~34.056) 0.529 0.855 (0.522~1.402)
 Yes 42 32 22 (10.886~33.114)   
  1. Histological grade: I, high differentiated ESCC; II, moderately differentiated ESCC; III, poorly differentiated ESCC
  2. Treatment: Radiotherapy or chemotherapy after surgery